Improving administration regimens of CyaA-based vaccines using TRAP assays to detect antigen-specific CD8+ T cells directly ex vivo

Vaccine

Volumn 27, Issue 41, 2009, Pages 5565-5573

  Daubeuf, Sandrine ^a,b   Préville, Xavier ^c   Momot, Marie ^c   Misseri, Yolande ^c   Joly, Etienne ^a,b   Hudrisier, Denis ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c BT PHARMA SA   (France)

Author keywords

Cytotoxic T lymphocytes; Trogocytosis; Vaccination

Indexed keywords

ADENYLATE CYCLASE; OVALBUMIN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BORDETELLA PERTUSSIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG TARGETING; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TROGOCYTOSIS ANALYSIS PROTOCOL ASSAY; VACCINATION;

ADENYLATE CYCLASE TOXIN; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; OVALBUMIN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC;

EID: 68949178552     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.035     Document Type: Article

References (48)

1. Guermonprez P., Khelef N., Blouin E., Rieu P., Ricciardi-Castagnoli P., Guiso N., et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 193 May 7 (9) (2001) 1035-1044
2. Guermonprez P., Fayolle C., Rojas M.J., Rescigno M., Ladant D., and Leclerc C. In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c + CD8 alpha-CD11bhigh dendritic cells. Eur J Immunol 32 November (11) (2002) 3071-3081
3. El Azami El Idrissi M., Ladant D., and Leclerc C. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 40 December (12) (2002) 1661-1665
4. Simsova M., Sebo P., and Leclerc C. The adenylate cyclase toxin from Bordetella pertussis-a novel promising vehicle for antigen delivery to dendritic cells. Int J Med Microbiol 293 April (7-8) (2004) 571-576
5. Fayolle C., Sebo P., Ladant D., Ullmann A., and Leclerc C. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol 156 June 15 (12) (1996) 4697-4706
6. Fayolle C., Bauche C., Ladant D., and Leclerc C. Bordetella pertussis adenylate cyclase delivers chemically coupled CD8+ T-cell epitopes to dendritic cells and elicits CTL in vivo. Vaccine 23 December 16 (5) (2004) 604-614
7. Schlecht G., Loucka J., Najar H., Sebo P., and Leclerc C. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J Immunol 173 November 15 (10) (2004) 6089-6097
8. Dadaglio G., Moukrim Z., Lo-Man R., Sheshko V., Sebo P., and Leclerc C. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect Immun 68 July (7) (2000) 3867-3872
9. Saron M.F., Fayolle C., Sebo P., Ladant D., Ullmann A., and Leclerc C. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 94 April 1 (7) (1997) 3314-3319
10. Fayolle C., Osickova A., Osicka R., Henry T., Rojas M.J., Saron M.F., et al. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J Virol 75 August (16) (2001) 7330-7338
11. Preville X., Ladant D., Timmerman B., and Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 65 January 15 (2) (2005) 641-649
12. Berraondo P., Nouze C., Preville X., Ladant D., and Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 67 September 15 (18) (2007) 8847-8855
13. Majlessi L., Simsova M., Jarvis Z., Brodin P., Rojas M.J., Bauche C., et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 74 April (4) (2006) 2128-2137
14. Hervas-Stubbs S., Majlessi L., Simsova M., Morova J., Rojas M.J., Nouze C., et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 74 June (6) (2006) 3396-3407
15. Dadaglio G., Morel S., Bauche C., Moukrim Z., Lemonnier F.A., Van Den Eynde B.J., et al. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. Int Immunol 15 December (12) (2003) 1423-1430
16. Karimova G., Fayolle C., Gmira S., Ullmann A., Leclerc C., and Ladant D. Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells. Proc Natl Acad Sci USA 95 October 13 (21) (1998) 12532-12537
17. Fayolle C., Ladant D., Karimova G., Ullmann A., and Leclerc C. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol 162 (1999) 4157-4162
18. Mascarell L., Fayolle C., Bauche C., Ladant D., and Leclerc C. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J Virol 79 August (15) (2005) 9872-9884
19. Fayolle C., Abdel-Motal U.M., Berg L., Deriaud E., Jondal M., and Leclerc C. Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology 89 1 (1996) 41-45
20. Guermonprez P., Ladant D., Karimova G., Ullmann A., and Leclerc C. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J Immunol 162 February 15 (4) (1999) 1910-1916
21. Sebo P., Moukrim Z., Kalhous M., Schaft N., Dadaglio G., Sheshko V., et al. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8(+) T-cell epitope. FEMS Immunol Med Microbiol 26 November (2) (1999) 167-173
22. Mascarell L., Bauche C., Fayolle C., Diop O.M., Dupuy M., Nougarede N., et al. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates. Vaccine 24 April 24 (17) (2006) 3490-3499
23. Loucka J., Schlecht G., Vodolanova J., Leclerc C., and Sebo P. Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect Immun 70 February (2) (2002) 1002-1005
24. Macdonald-Fyall J., Xing D., Corbel M., Baillie S., Parton R., and Coote J. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens. Vaccine 22 October 22 (31-32) (2004) 4270-4281
25. Daubeuf S., Puaux A., Joly E., and Hudrisier D. A simple trogocytosis-based method to detect, quantify, characterize and purify antigen-specific live lymphocytes by flow cytometry, via their capture of membrane fragments from antigen-presenting cells. Nat Prot 1 (2007) 2536-2542
26. Hudrisier D., Riond J., Mazarguil H., Gairin J.E., and Joly E. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol 166 6 (2001) 3645-3649
27. Daubeuf S., Aucher A., Sampathkumar S., Preville X., Yarema K., and Hudrisier D. Chemical labels metabolically installed into the glycoconjugates of the target cell surface can be used to track lymphocyte/target cell interplay via trogocytosis: comparisons with lipophilic dyes and biotin. Immunol Invest 36 (2007) 687-712
28. Puaux A., Campanaud J., Salles A., Preville X., Timermann B., Joly E., et al. A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cells reactivity by flow cytometry. Eur J Immunol 36 (2006) 779-788
29. Beadling C., and Slifka M. Quantifying viable virus-specific T cells without a priori knowledge of fine epitope specificity. Nat Med 12 (2006) 1208-1212
30. Machlenkin A., Uzana R., Frankenburg S., Eisenberg G., Eisenbach L., Pitcovski J., et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res 68 March 15 (6) (2008) 2006-2013
31. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., and Carbone F.R. T-cell receptor antagonist peptides induce positive selection. Cell 76 1 (1994) 17-27
32. Guermonprez P., Fayolle C., Karimova G., Ullmann A., Leclerc C., and Ladant D. Bordetella pertussis adenylate cyclase toxin: a vehicle to deliver CD8-positive T-cell epitopes into antigen-presenting cells. Methods Enzymol 326 (2000) 527-542
33. Daubeuf S., Bordier C., Hudrisier D., and Joly E. Suitability of various membrane lipophilic probes for the detection of trogocytosis by flow cytometry. Cytometry 75A (2008) 380-389
34. Vitiello A., Heath W.R., and Sherman L.A. Consequences of self-presentation of peptide antigen by cytolytic T lymphocytes. J Immunol 143 September 1 (5) (1989) 1512-1517
35. Viola A., Salio M., Tuosto L., Linkert S., Acuto O., and Lanzavecchia A. Quantitative contribution of CD4 and CD8 to T cell antigen receptor serial triggering. J Exp Med 186 10 (1997) 1775-1779
36. McFarland H.I., Nahill S.R., Maciaszek J.W., and Welsh R.M. CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol 149 4 (1992) 1326-1333
37. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 October 14 (6754) (1999) 708-712
38. Hara T., Jung L.K., Bjorndahl J.M., and Fu S.M. Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med 164 December 1 (6) (1986) 1988-2005
39. Riond J., Elhmouzi F., Hudrisier D., and Gairin J. Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8+ CTL. Scand J Immunol 66 (2007) 441-450
40. Verbeek R., van der Mark K., Wawrousek E.F., Plomp A.C., and van Noort J.M. Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen. Immunology 121 July (3) (2007) 416-426
41. Peixoto A., Evaristo C., Munitic I., Monteiro M., Charbit A., Rocha B., et al. CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response. J Exp Med 204 May 14 (5) (2007) 1193-1205
42. Ueno H., Klechevsky E., Morita R., Aspord C., Cao T., Matsui T., et al. Dendritic cell subsets in health and disease. Immunol Rev 219 October (2007) 118-142
43. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
44. Picker L.J., Singh M.K., Zdraveski Z., Treer J.R., Waldrop S.L., Bergstresser P.R., et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86 August 15 (4) (1995) 1408-1419
45. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., and Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65 December 16 (1-2) (1983) 109-121
46. Klenerman P., Cerundolo V., and Dunbar P.R. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2 April (4) (2002) 263-272
47. Constantin C.M., Bonney E.E., Altman J.D., and Strickland O.L. Major histocompatibility complex (MHC) tetramer technology: an evaluation. Biol Res Nurs 4 October (2) (2002) 115-127
48. Vollers S.S., and Stern L.J. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 123 March (3) (2008) 305-313